RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki z wczesnym rakiem piersi (stopnia I-III), które będą przyjmować chemioterapię.
- •Pacjentki, które nie miały wcześniej chemioterapii, radioterapii ani innych leków na raka piersi lub inną chorobę nowotworową.
- •Pacjentki w wieku 18 lat lub starsze.
- •Pacjentki, których organizm dobrze znosi standardowe leczenie i które mają dobre wyniki badań krwi oraz narządów (np. wątroby, nerek).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- December 24, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (3)
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., United States
Medstar Washington Hospital Center
Washington D.C., United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, United States
Trial contact
Lana Kheir
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.